166 related articles for article (PubMed ID: 3891875)
1. Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi.
Ruiter DJ; Dingjan GM; Steijlen PM; van Beveren-Hooyer M; de Graaff-Reitsma C; Bergman W; van Muijen GN; Warnaar SO
J Invest Dermatol; 1985 Jul; 85(1):4-8. PubMed ID: 3891875
[TBL] [Abstract][Full Text] [Related]
2. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
3. Common acquired melanocytic nevi, melanocytic dysplasia and malignant melanoma. A morphometric study.
Santucci M; Urso C; Giannini A; Bondi R
Appl Pathol; 1989; 7(2):111-5. PubMed ID: 2730799
[TBL] [Abstract][Full Text] [Related]
4. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
5. Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi.
Saab J; Santos-Zabala ML; Loda M; Stack EC; Hollmann TJ
Am J Dermatopathol; 2018 Apr; 40(4):259-264. PubMed ID: 28654463
[TBL] [Abstract][Full Text] [Related]
6. Increased intraepidermal melanocyte frequency and size in dysplastic melanocytic nevi and cutaneous melanoma. A comparative quantitative study of dysplastic melanocytic nevi, superficial spreading melanoma, nevocellular nevi, and solar lentigines.
Rhodes AR; Melski JW; Sober AJ; Harrist TJ; Mihm MC; Fitzpatrick TB
J Invest Dermatol; 1983 May; 80(5):452-9. PubMed ID: 6341476
[TBL] [Abstract][Full Text] [Related]
7. Use of monoclonal antibodies in detection of melanoma-associated antigens in intact human tumors.
Thompson JJ; Herlyn MF; Elder DE; Clark WH; Steplewski Z; Koprowski H
Am J Pathol; 1982 Jun; 107(3):357-61. PubMed ID: 6177248
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical studies of conjunctival nevi and melanomas.
Jakobiec FA; Bhat P; Colby KA
Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens.
Ruiter DJ; Bergman W; Welvaart K; Scheffer E; van Vloten WA; Russo C; Ferrone S
Cancer Res; 1984 Sep; 44(9):3930-5. PubMed ID: 6204749
[TBL] [Abstract][Full Text] [Related]
10. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions.
Trefzer U; Rietz N; Chen Y; Audring H; Herberth G; Siegel P; Reinke S; Königer P; Wu S; Ma J; Liu Y; Wang H; Sterry W; Guo Y
Arch Dermatol Res; 2000 Dec; 292(12):583-9. PubMed ID: 11214818
[TBL] [Abstract][Full Text] [Related]
11. Expression of NM23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin.
Reichrath J; Seyfried P; Braun R; Müller SM; Baum HP; Bahmer FA
Dermatology; 1997; 194(2):136-9. PubMed ID: 9094461
[TBL] [Abstract][Full Text] [Related]
12. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations.
Rodić N; Zampella J; Sharma R; Burns KH; Taube JM
J Cutan Pathol; 2015 Nov; 42(11):807-14. PubMed ID: 26239102
[TBL] [Abstract][Full Text] [Related]
14. Lymph node melanocytic nevi: pathogenesis and differential diagnoses, with special reference to p16 reactivity.
Piana S; Tagliavini E; Ragazzi M; Zanelli M; Zalaudek I; Ciarrocchi A; Valli R
Pathol Res Pract; 2015 May; 211(5):381-8. PubMed ID: 25661066
[TBL] [Abstract][Full Text] [Related]
15. Melanocytic nevi in sentinel lymph nodes: association with cutaneous nevi and clinical relevance in patients with cutaneous melanomas.
Kretschmer L; Schnabel V; Kromer C; Bauer-Büntzel C; Richter A; Bremmer F; Kück F; Julius K; Mitteldorf C; Schön MP
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3125-3134. PubMed ID: 35059868
[TBL] [Abstract][Full Text] [Related]
16. Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin.
Bröcker EB; Magiera H; Herlyn M
J Invest Dermatol; 1991 May; 96(5):662-5. PubMed ID: 1850772
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes.
Gown AM; Vogel AM; Hoak D; Gough F; McNutt MA
Am J Pathol; 1986 May; 123(2):195-203. PubMed ID: 3518473
[TBL] [Abstract][Full Text] [Related]
18. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi.
Holt JB; Sangueza OP; Levine EA; Shen P; Bergman S; Geisinger KR; Creager AJ
Am J Clin Pathol; 2004 Jan; 121(1):58-63. PubMed ID: 14750241
[TBL] [Abstract][Full Text] [Related]
19. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000.
Lehmann JM; Holzmann B; Breitbart EW; Schmiegelow P; Riethmüller G; Johnson JP
Cancer Res; 1987 Feb; 47(3):841-5. PubMed ID: 3542195
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tubulin β-3 and 5 hydroxy-methyl cytosine as diagnostic and prognostic markers in malignant melanoma.
Katarzyna L; Kyriakos O; Linda V; Ingrid S; Petra W; Karin Ö
Ann Diagn Pathol; 2024 Oct; 72():152332. PubMed ID: 38776734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
